Pioglitazone and metformin fixed-dose combination in type 2 diabetes mellitus: An evidence-based review of its place in therapy

Research output: Contribution to journalArticle

Abstract

Introduction: Type 2 diabetes mellitus, a metabolic disease with increasing incidence, is one of the most important cardiovascular risk factors. Insulin resistance represents the common mechanism that leads to type 2 diabetes in obese subjects. Metformin and the thiazolidinediones, pioglitazone and rosiglitazone, are insulin-sensitizing agents available for treatment of type 2 diabetes. Large clinical trials have demonstrated the effectiveness of both metformin and pioglitazone in reducing cardiovascular morbidity and mortality. The fixed-dose combination of metformin and pioglitazone appears to be a good option for treating diabetes in insulin-resistant patients. Aims: The purpose of this article is to review the place in therapy of a fixed-dose combination of pioglitazone and metformin in the management of patients with type 2 diabetes. Evidence review: The current evidence suggests that combined therapy may help to achieve the recommended goals in the management of diabetes. A fixed-dose formulation of pioglitazone and metformin may provide advantages in terms of glycemic control and other cardiovascular risk factors frequently associated with diabetes. Place in therapy: The current evidence shows that a fixed-dose formulation of pioglitazone and metformin offers an effective option for the management of patients with type 2 diabetes when monotherapy fails in the achievement of the recommended standards of care.

Original languageEnglish
Pages (from-to)189-198
Number of pages10
JournalCore Evidence
Volume2
Issue number3
Publication statusPublished - 2008

Fingerprint

pioglitazone
Metformin
Type 2 Diabetes Mellitus
rosiglitazone
Therapeutics
Insulin
Thiazolidinediones
Metabolic Diseases
Standard of Care
Insulin Resistance
Clinical Trials

Keywords

  • Cardiovascular risk factors
  • Diabetes
  • Metformin
  • Outcomes
  • Pioglitazone

ASJC Scopus subject areas

  • Medicine(all)
  • Reviews and References, Medical
  • Pharmacology

Cite this

@article{b46d50f0d9744d71b8718e5b6be3acc4,
title = "Pioglitazone and metformin fixed-dose combination in type 2 diabetes mellitus: An evidence-based review of its place in therapy",
abstract = "Introduction: Type 2 diabetes mellitus, a metabolic disease with increasing incidence, is one of the most important cardiovascular risk factors. Insulin resistance represents the common mechanism that leads to type 2 diabetes in obese subjects. Metformin and the thiazolidinediones, pioglitazone and rosiglitazone, are insulin-sensitizing agents available for treatment of type 2 diabetes. Large clinical trials have demonstrated the effectiveness of both metformin and pioglitazone in reducing cardiovascular morbidity and mortality. The fixed-dose combination of metformin and pioglitazone appears to be a good option for treating diabetes in insulin-resistant patients. Aims: The purpose of this article is to review the place in therapy of a fixed-dose combination of pioglitazone and metformin in the management of patients with type 2 diabetes. Evidence review: The current evidence suggests that combined therapy may help to achieve the recommended goals in the management of diabetes. A fixed-dose formulation of pioglitazone and metformin may provide advantages in terms of glycemic control and other cardiovascular risk factors frequently associated with diabetes. Place in therapy: The current evidence shows that a fixed-dose formulation of pioglitazone and metformin offers an effective option for the management of patients with type 2 diabetes when monotherapy fails in the achievement of the recommended standards of care.",
keywords = "Cardiovascular risk factors, Diabetes, Metformin, Outcomes, Pioglitazone",
author = "Giuseppe Derosa and Salvadeo, {S. A T}",
year = "2008",
language = "English",
volume = "2",
pages = "189--198",
journal = "Core Evidence",
issn = "1555-1741",
publisher = "Dove Medical Press Ltd.",
number = "3",

}

TY - JOUR

T1 - Pioglitazone and metformin fixed-dose combination in type 2 diabetes mellitus

T2 - An evidence-based review of its place in therapy

AU - Derosa, Giuseppe

AU - Salvadeo, S. A T

PY - 2008

Y1 - 2008

N2 - Introduction: Type 2 diabetes mellitus, a metabolic disease with increasing incidence, is one of the most important cardiovascular risk factors. Insulin resistance represents the common mechanism that leads to type 2 diabetes in obese subjects. Metformin and the thiazolidinediones, pioglitazone and rosiglitazone, are insulin-sensitizing agents available for treatment of type 2 diabetes. Large clinical trials have demonstrated the effectiveness of both metformin and pioglitazone in reducing cardiovascular morbidity and mortality. The fixed-dose combination of metformin and pioglitazone appears to be a good option for treating diabetes in insulin-resistant patients. Aims: The purpose of this article is to review the place in therapy of a fixed-dose combination of pioglitazone and metformin in the management of patients with type 2 diabetes. Evidence review: The current evidence suggests that combined therapy may help to achieve the recommended goals in the management of diabetes. A fixed-dose formulation of pioglitazone and metformin may provide advantages in terms of glycemic control and other cardiovascular risk factors frequently associated with diabetes. Place in therapy: The current evidence shows that a fixed-dose formulation of pioglitazone and metformin offers an effective option for the management of patients with type 2 diabetes when monotherapy fails in the achievement of the recommended standards of care.

AB - Introduction: Type 2 diabetes mellitus, a metabolic disease with increasing incidence, is one of the most important cardiovascular risk factors. Insulin resistance represents the common mechanism that leads to type 2 diabetes in obese subjects. Metformin and the thiazolidinediones, pioglitazone and rosiglitazone, are insulin-sensitizing agents available for treatment of type 2 diabetes. Large clinical trials have demonstrated the effectiveness of both metformin and pioglitazone in reducing cardiovascular morbidity and mortality. The fixed-dose combination of metformin and pioglitazone appears to be a good option for treating diabetes in insulin-resistant patients. Aims: The purpose of this article is to review the place in therapy of a fixed-dose combination of pioglitazone and metformin in the management of patients with type 2 diabetes. Evidence review: The current evidence suggests that combined therapy may help to achieve the recommended goals in the management of diabetes. A fixed-dose formulation of pioglitazone and metformin may provide advantages in terms of glycemic control and other cardiovascular risk factors frequently associated with diabetes. Place in therapy: The current evidence shows that a fixed-dose formulation of pioglitazone and metformin offers an effective option for the management of patients with type 2 diabetes when monotherapy fails in the achievement of the recommended standards of care.

KW - Cardiovascular risk factors

KW - Diabetes

KW - Metformin

KW - Outcomes

KW - Pioglitazone

UR - http://www.scopus.com/inward/record.url?scp=65849142786&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65849142786&partnerID=8YFLogxK

M3 - Article

C2 - 21221185

AN - SCOPUS:65849142786

VL - 2

SP - 189

EP - 198

JO - Core Evidence

JF - Core Evidence

SN - 1555-1741

IS - 3

ER -